VANCOUVER, BC–(Marketwired – October 23, 2016) – BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness.
Investors are increasingly using digital media and non-traditional media outlets to identify potential investment opportunities. Recent research indicates that more than 70% of institutional and retail investors are “connected investors” who utilize information derived from digital media to guide their investment decisions. Rising Tide Equity meets the needs of connected investors by identifying select emerging growth companies and connecting them with their stories through digital media engagement.
Rob Hutchison, biOasis CEO, stated, “With our company’s move into its commercialization phase, it is critical for us to reach a broader base of communities, from investors to institutional groups, in essence to the global public in general. Rising Tide is lead by Dr. Josh McGuire, former SERE Psychologist at the Department of Defense and Chief Psychologist, Competency Program, Texas Department of Health Services. With Josh’s broad experience, Rising Tide Equity has adopted unique dissemination methods that reach and capture global communities. Further, Josh’s professional background ideally fits with our technology because of his understanding of the significant impact Transcend can have on CNS treatment therapies.”
“We set a high bar for the companies with whom we look to engage. Using our Evidenced Based investing philosophy, we believe that biOasis represents a compelling opportunity,” said Dr. Josh McGuire, CEO, Rising Tide Equity. “We provide comprehensive equity reports, regular corporate updates, CEO interviews, and a multitude of other services that create greater public awareness. Taken together with our revolutionary content dissemination methods, our multifaceted and targeted approach increases global awareness. biOasis, in my opinion, is a unique company that is relatively undiscovered at this time and we are looking forward to working with them. Our initial reports on biOasis can be found starting Monday, October 24th 2016 at https://www.risingtideequity.com/category/bioasis/.”
About Rising Tide
Rising Tide Equity provides investors with information to prosper in an increasingly complex stock market. We provide comprehensive equity reports on select emerging growth companies. Our eclectic management team, with over 50 years in the capital markets, uses an Evidence Based Investing approach to filter out the noise and identify compelling investments. We use reasoned analysis to evaluate each company examining the fundamental characteristics, market potential, and opportunity for further growth while engaging company leadership to assess their ability to achieve corporate goals. Use our Evidence Based approach to gain an investing edge.
About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Rob Hutchison, Chair & CEO
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
Company Contact
Rob Hutchison
biOasis Technologies Inc.
info@bioasis.ca
1-604-644-1232